99858-57-8

Basic information

• Product Name: 1-Butanol, 4-[(phenylmethylene)amino]-
• CAS NO: 99858-57-8
• Molecular Formula: C11H15NO
• Molecular Weight: 177.246
• Mol File: 99858-57-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-Butanol, 4-[(phenylmethylene)amino]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Butanol, 4-[(phenylmethylene)amino]-(99858-57-8)
• EPA Substance Registry System: 1-Butanol, 4-[(phenylmethylene)amino]-(99858-57-8)

Safety Data

• Hazardous Substances Data: 99858-57-8(Hazardous Substances Data)

Upstream product

• 13325-10-5 4-Aminobutanol 
• 100-52-7 benzaldehyde 

Downstream Products

• 117654-86-1 4-[N-(t-butoxycarbonyl)-N-[(phenyl)methyl]-amino]butan-1-ol 
• 635304-19-7 toluene-4-sulfonic acid 4-(benzyl-tert-butoxycarbonyl-amino)-butyl ester 
• 213772-66-8 6-[4-(N-tert-Butoxycarbonyl-N-phenylmethylamino)-butylamino]-hexan-1-ol 
• 213772-92-0 [4-(benzyl-tert-butoxycarbonyl-amino)-butyl]-(6-hydroxy-hexyl)-carbamic acid tert-butyl ester 
• 213773-07-0 N-(N'-benzyl-N'-tert-butoxycarbonyl-4-aminobutyl)-N-tert-butoxycarbonyl-6-aminohexanoic acid 
• 29897-82-3 N-benzylpyrrolidine 
• 874915-60-3 N-benzyl-N-(4-hydroxybutyl)acetamide 
• 91245-77-1 1-benzylpyrrolidine hydrochloride 
• 59578-63-1 4-(benzylamino)-1-butanol 

Relevant articles and documents

Defining the Molecular Requirements for the Selective Delivery of Polyamine Conjugates into Cells Containing Active Polyamine Transporters

Several N1-substituted polyamines containing various spacer units between nitrogen centers were synthesized as their respective HCl salts. The N1-substituents included benzyl, naphthalen-1-ylmethyl, anthracen-9-ylmethyl, and pyren-1-

Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension

Prostacyclin controls cardiovascular function via activation of the prostacyclin receptor. Decreased prostacyclin production occurs in several cardiovascular diseases. However, the clinical use of prostacyclin and its analogues is complicated by their chemical and metabolic instability. A medicinal chemistry program searched for novel nonprostanoid prostacyclin receptor agonists not subject to these limitations. A compound with a diphenylpyrazine structural core was synthesized. Metabolic stability and agonist potency were optimized through modification of the linear side chain. Compound 12b (MRE-269, ACT-333679) was identified as a potent and highly selective prostacyclin receptor agonist. Replacement of the terminal carboxyl group with an N-acylsulfonamide group yielded parent compound 26a (selexipag, NS-304, ACT-293987), which is orally active and provides sustained plasma exposure of 12b. Compound 26a was developed for the treatment of pulmonary arterial hypertension and shown to reduce the risk of the composite morbidity/mortality end point in a phase 3 event-driven clinical trial.

Efficient, stereodivergent access to 3-piperidinols by traceless P(OEt)3 cyclodehydration

A stereodivergent and highly diastereoselective (dr up to >19:1 for both isomers), step economic (5-6 steps), and scalable synthesis (up to 14 g) of cis- and trans-2-substituted 3-piperidinols, the core motif of numerous bioactive compounds, providing efficient access to the NK-1 inhibitor L-733,060 is presented. Additionally, a "traceless" (referring to the simplified byproduct separation) cyclodehydration realizing simple P(OEt)3 as a substitute for PPh3 is developed.